NEW YORK (GenomeWeb News) – Swiss biochemical extraction company Spinomix has closed a Series A equity investment of $3 million, with the funds coming from existing and new investors, the company said today.

The round of financing was led by Debiopharm Group, a collection of biopharmaceutical companies focused on drug development and investing in startups, primarily in the molecular diagnostics and personalized medicine fields. The funding also included support from previous investors and a private, undisclosed US-based investor group.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

Aug
20
Sponsored by
Canon BioMedical

This webinar will provide an overview of recent advances in single-cell RNA sequencing from the perspectives of three research organizations.